Supernus Pharmaceuticals Inc (NASDAQ:SUPN) had its price objective lifted by equities research analysts at Cantor Fitzgerald from $34.00 to $49.00 in a research note issued on Wednesday. The brokerage presently has a “buy” rating on the specialty pharmaceutical company’s stock. Cantor Fitzgerald’s price objective would suggest a potential upside of 13.56% from the stock’s current price.

Several other equities research analysts also recently commented on SUPN. Jefferies Group LLC boosted their target price on shares of Supernus Pharmaceuticals from $45.00 to $51.00 and gave the company a “buy” rating in a research note on Wednesday, June 28th. BidaskClub upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 24th. Piper Jaffray Companies upgraded shares of Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their target price for the company from $30.00 to $44.00 in a research note on Thursday, June 1st. Cowen and Company boosted their target price on shares of Supernus Pharmaceuticals from $31.00 to $34.00 and gave the company an “outperform” rating in a research note on Thursday, May 11th. Finally, Stifel Nicolaus boosted their target price on shares of Supernus Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, April 3rd. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $37.43.

Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) traded up 0.70% during midday trading on Wednesday, reaching $43.15. 452,098 shares of the company were exchanged. Supernus Pharmaceuticals has a 52-week low of $17.25 and a 52-week high of $44.95. The stock’s 50-day moving average price is $38.15 and its 200-day moving average price is $30.48. The company has a market capitalization of $2.17 billion, a PE ratio of 23.21 and a beta of 1.34.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported $0.19 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.22 by $0.03. The business had revenue of $57.58 million during the quarter, compared to the consensus estimate of $57.91 million. Supernus Pharmaceuticals had a net margin of 17.88% and a return on equity of 20.76%. Analysts anticipate that Supernus Pharmaceuticals will post $1.02 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This news story was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of international copyright laws. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/07/09/supernus-pharmaceuticals-inc-nasdaqsupn-pt-raised-to-49-00.html.

In other Supernus Pharmaceuticals news, CFO Gregory S. Patrick sold 54,000 shares of the company’s stock in a transaction dated Monday, April 24th. The shares were sold at an average price of $32.37, for a total transaction of $1,747,980.00. Following the transaction, the chief financial officer now directly owns 54,221 shares in the company, valued at approximately $1,755,133.77. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Padmanabh P. Bhatt sold 11,806 shares of the company’s stock in a transaction dated Monday, April 24th. The shares were sold at an average price of $32.59, for a total transaction of $384,757.54. Following the transaction, the vice president now owns 45,500 shares in the company, valued at $1,482,845. The disclosure for this sale can be found here. In the last quarter, insiders have sold 86,362 shares of company stock worth $2,927,802. 6.70% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. increased its position in Supernus Pharmaceuticals by 156,173.3% in the first quarter. BlackRock Inc. now owns 6,696,310 shares of the specialty pharmaceutical company’s stock worth $209,595,000 after buying an additional 6,692,025 shares during the last quarter. Vanguard Group Inc. increased its position in Supernus Pharmaceuticals by 6.6% in the first quarter. Vanguard Group Inc. now owns 2,516,335 shares of the specialty pharmaceutical company’s stock worth $78,762,000 after buying an additional 156,094 shares during the last quarter. Bank of New York Mellon Corp increased its position in Supernus Pharmaceuticals by 4.9% in the first quarter. Bank of New York Mellon Corp now owns 1,668,864 shares of the specialty pharmaceutical company’s stock worth $52,236,000 after buying an additional 78,084 shares during the last quarter. Ranger Investment Management L.P. increased its position in Supernus Pharmaceuticals by 2.8% in the first quarter. Ranger Investment Management L.P. now owns 1,482,535 shares of the specialty pharmaceutical company’s stock worth $46,403,000 after buying an additional 40,131 shares during the last quarter. Finally, State Street Corp increased its position in Supernus Pharmaceuticals by 4.0% in the first quarter. State Street Corp now owns 1,355,319 shares of the specialty pharmaceutical company’s stock worth $42,422,000 after buying an additional 52,091 shares during the last quarter. Institutional investors own 91.38% of the company’s stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.